CTT Pharmaceutical Holdings, Inc. (CTTH)
| Market Cap | 2.85M -6.0% |
| Revenue (ttm) | n/a |
| Net Income | -211.04K |
| EPS | -0.00 |
| Shares Out | 58.71M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,960 |
| Open | 0.0449 |
| Previous Close | 0.0500 |
| Day's Range | 0.0449 - 0.0491 |
| 52-Week Range | 0.0350 - 0.1000 |
| Beta | 0.72 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 11, 2026 |
About CTTH
CTT Pharmaceutical Holdings, Inc. engages in the development of oral drug delivery systems for pain management and treatment. It focuses on fast dissolving drug delivery systems. The company’s technology platform includes the development of advanced oral delivery thin wafers infused with both natural and/or synthetic cannabis extracts to deliver treatment as an alternate to smoking and ingestion. Its principal asset is a patented orally administered dissolvable strip. The company is based in Tampa, Florida. [Read more]
Full Company ProfileFinancial Performance
Financial StatementsNews
CTT Pharma Files a Patent Continuation with the U.S. Patent Office
The Newswire – August 18, 2026 - CTT Pharmaceutical Holdings, Inc. (OTCQB:CTTH) has filed a patent continuation with the United States Patent Office. This patent application is a continuation of CTT P...
CTT Pharma Corporate Updates
August 12, 2026 – TheNewswire - CTT Pharmaceutical Holdings, Inc. (OTCQB:CTTH) has been looking to acquire a facility for manufacturing and has recently expanded its search for a partnership with a co...
CTT Pharma Receives U.S. Patent Approval for Nicotine, Vitamins, and Caffeine Delivery Technology
August 10, 2026 – TheNewswire - CTT Pharmaceutical Holdings, Inc. (OTCQB:CTTH) is pleased to announce the company has been formally approved by the U.S. Patent Office for a continuation-in-part(CIP). ...
CTT Pharma Receives SEC Approval
August 5, 2026 – TheNewswire - CTT Pharmaceutical Holdings, Inc. (OTCQB:CTTH) is pleased to announce the company has been formally approved by the SEC for our S-1 and will now be a SEC reporting compa...
CTT Pharma Signs LOI for Clinical Trials and Testing of Nicotine Products
TAMPA, FL / ACCESS Newswire / June 22, 2026 / CTT Pharmaceutical Holdings, Inc. (OTCQB:CTTH) has signed an LOI with a testing company in the United States to conduct clinical trials and testing for se...
CTT Pharma Signs LOI with European Company
TAMPA, FL / ACCESS Newswire / June 17, 2026 / CTT Pharmaceutical Holdings, Inc. (OTCQB:CTTH) has signed an LOI with a company in the United States to conduct clinical trials and testing for several po...
CTT Pharmaceutical Holdings, Inc. Files Form S-1 Registration Statement and Advances Equity Line of Credit and Scientific Development Milestones
TAMPA, FL / ACCESS Newswire / December 30, 2025 / CTT Pharmaceutical Holdings, Inc. (OTCQB:CTTH) today announces the filing of a Form S-1 registration statement with the United States Securities and E...
CTT Pharma's Scientists Publish Peer-Reviewed Paper in the Journal of Drug Delivery and Therapeutics
TAMPA, FL / ACCESS Newswire / December 16, 2025 / (OTCQB:CTTH) CTT Pharmaceutical Holdings, Inc. is pleased to announce that a peer-reviewed scientific paper has been published in the journal of Drug ...
CTT Pharma's CEO will issue a Letter to Shareholders
Tampa, Florida, United States – TheNewswire – November 20, 2025 - CTT Pharmaceutical Holdings, Inc.(OTCQB:CTTH) is pleased to announce that the CEO of CTT Pharma will issue a letter to shareholders on...
CTT Pharma Signs Contract for $3 Million Equity Line of Credit
Tampa, Florida, United States – TheNewswire – September 10, 2025 – CTT Pharmaceuticals Holdings, Inc. (OTCQB:CTTH) is pleased to announce it has signed a contract for a $3 Million Equity Line of Credi...